Posted by Michael Wonder on 12 May 2025
Erdafitinib for the treatment of patients with unresectable or metastatic urothelial cancer with an FGFR3 alteration after a PD-1 or PD-L1 inhibitor
12 May 2025 - Erdafitinib is recommended as an option for the treatment of adults with unresectable or metastatic urothelial cancer with a susceptible FGFR3 genetic alteration after at least one line of treatment for unresectable or metastatic cancer that included a PD‑1 or PD‑L1 inhibitor.
Erdafitinib is only recommended if Janssen provides it according to the commercial arrangement.
